SCHEMBL4780073

SCHEMBL4780073

S=C=NCc1ccc(Br)cc1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MIF P14174 12/20 0.63
TRPA1 O75762 3/20 0.63
ALDH1A1 P00352 1/20 0.61
CYP3A4 P08684 1/20 0.61
HPGD P15428 1/20 0.61
HTR2A P28223 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
CYP2A6 P11509 2/20 0.38
CYP2E1 P05181 1/20 0.38
HIF1A Q16665 1/20 0.38
CYP2A13 Q16696 1/20 0.38
EPAS1 Q99814 1/20 0.38
IDO1 P14902 2/20 0.37
P2RY6 Q15077 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2141861 0.88 MIF (0.77) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL8763362 0.81 MIF (0.68) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL14925996 0.77 TAAR1 (0.38) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL5790355 0.77 MIF (0.63) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL10651884 0.77 TRPA1 (0.69) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL1647922 0.77 PYCR1 (0.39) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL895951 0.77 MIF (0.64) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL1457562 0.77 MIF (1.00) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL1706732 0.77 MIF (0.63) MIFTRPA1ALDH1A1CYP3A4HPGD
SCHEMBL14476253 0.77 MIF (0.63) MIFTRPA1ALDH1A1CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110973149-B Application of sulfur-containing isocyanate compounds in blue-green algae growth inhibition 华中师范大学 2021-09-14 CN disclosed
CN-110973149-A Application of sulfur-containing isocyanate compounds in blue-green algae growth inhibition 华中师范大学 2020-04-10 CN disclosed
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2014-06-19 US disclosed
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2014-06-19 US disclosed
EP-2725024-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2014-04-30 EP disclosed
US-20130116203-A1 ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-05-09 US disclosed
US-20130116203-A1 ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-05-09 US disclosed
US-20130116203-A1 ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-05-09 US disclosed
US-20080312164-A1 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 US disclosed
US-20080312164-A1 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 US disclosed
US-20080312164-A1 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 US disclosed
WO-2008008954-A2 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-01-17 WO disclosed
WO-2008008954-A2 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-01-17 WO disclosed
WO-2005024755-A2 MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES DECIPHERA PHARMACEUTICALS, LLC. (US) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE PLA2G5, LTA4H, PLA2G4A MIF 1652/4885TRPA1 1958/4885ALDH1A1 608/4885
US-20080312164-A1 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME GGCT, GSTK1, GCLC MIF 1422/4885TRPA1 2140/4885ALDH1A1 1045/4885
US-20130116203-A1 ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME GGCT, GSTK1, GSTA1 MIF 906/4885TRPA1 2349/4885ALDH1A1 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.